"As of now, semaglutide is FDA-indicated for slowing chronic kidney disease progression, [but] our results suggest that ...

In a state where the obesity rate ranks among the highest in the country, many were thrilled when Medicaid began covering GLP ...

Already-scarce Medicaid coverage of the highly touted weight loss drugs could become more limited, with federal Medicaid funding cuts expected in the wake of the massive tax-and-spending bill ...

Key Points Chesapeake sold 9,875 Eli Lilly and Company shares; estimated trade value of approximately $7.68 million, based on the average price for Q2 2025 Transaction represented 6.9% of fund AUM.

Strong sector performers stand out as AAPL, LLY, and V gain traction through services, drug demand, and digital payment ...

Few differences were found for cardiovascular, kidney, and mortality outcomes between liraglutide, semaglutide, and dulaglutide for patients with type 2 diabetes.

Fundamentally, Eli Lilly represents a juggernaut in medical innovations. Recently, the company has taken a leadership role in ...

Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.

Independence Bank of Kentucky disclosed a purchase of 4,193 shares of Eli Lilly and Company (NYSE: LLY), estimated at $3.12 million based on the average price for the quarter, in its SEC filing for ...

France’s medicines agency has referred multiple cases to prosecutors and has filed 20 reports against illicit sites through ...